METHYLPHENIDATE
Narcolepsy and attention-deficit hyperactivity disorder (ADHD)
Oral; 10-60 mg daily given in 2 or 3 divided doses.
hypersensitive to the drug, marked anxiety, tension, agitation, glaucoma, Tourette's syndrome, along with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor.
Paediatric: Safety not established in less than 6 years of age Pregnancy: category C; Use if risk to fetus outweighs benefits. Lactation: Not known if excreted in milk Elderly: May aggravate cardiac problems
nervousness, agitation, anxiety, insomnia, loss of appetite, nausea, vomiting, dizziness, palpitations, headache, increased heart rate, increased blood pressure, and psychosis.
Caffeine, pseudoephedrine, monoamine oxidase inhibitors (MAOIs), for example, isocarboxazid (Marplan).
